每周股票复盘：三生国健（688336）预计2025年净利29亿元

Core Viewpoint - Sangfor Biopharma (三生国健) is expected to achieve significant revenue and profit growth in 2025, driven by a collaboration with Pfizer and the recognition of substantial income from a project authorization fee. Group 1: Stock Performance - As of January 30, 2026, Sangfor Biopharma's stock closed at 60.22 CNY, up 2.48% from the previous week [1] - The stock reached a weekly high of 66.28 CNY on January 27 and a low of 56.88 CNY on January 26 [1] - The company's current total market capitalization is 37.221 billion CNY, ranking 7th out of 51 in the biopharmaceutical sector and 562nd out of 5184 in the A-share market [1] Group 2: Earnings Forecast - Sangfor Biopharma forecasts a total revenue of approximately 4.2 billion CNY for the year 2025 [4] - The company anticipates a net profit attributable to shareholders of around 2.9 billion CNY for 2025 [3] - The expected net profit after deducting non-recurring gains and losses is projected to be about 2.8 billion CNY, reflecting a year-on-year growth of approximately 1,038.21% [5][7] Group 3: Revenue Drivers - The significant growth in earnings is primarily attributed to the collaboration with Pfizer, which includes a project authorization fee that will contribute approximately 2.89 billion CNY to revenue [5][7] - The projected revenue growth represents an increase of about 251.76% compared to the previous year [5]